Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 511 to 525 of 1300 results for heart OR cardi* OR arrythmia

  1. Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)

    This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    General practice indicators suitable for use in QOF
    Published
    15 August 2024

  2. Cardiovascular disease prevention: risk assessment (general population) (IND269)

    This indicator covers the percentage of people aged 45 to 84 years who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    15 August 2024

  3. Mortality: cardiovascular disease (IND280)

    This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

    Network / system level indicators
    Published
    30 September 2023

  4. Monitoring after an intervention: What is the most clinically and cost‑effective timing, nature and frequency of follow up for different types of valve interventions, including repair and replacement with tissue or mechanical valves?

    in people with repaired or replaced heart valves. Source guidance details Comes from guidance Heart valve disease...

    Research recommendation
    Published
    16 December 2021

  5. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

    Evidence summary
    Published
    7 March 2017

  6. Abdominal aortic aneurysm: diagnosis and management (NG156)

    This guideline covers diagnosing and managing abdominal aortic aneurysms. It aims to improve care by helping people who are at risk to get tested, specifying how often to monitor asymptomatic aneurysms, and identifying when aneurysm repair is needed and which procedure will work best.

    NICE guideline
    Published
    19 March 2020
    View recommendations

    Sections for NG156

  7. Infliximab and adalimumab for the treatment of Crohn's disease (TA187)

    Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.

    Technology appraisal guidance
    Published
    19 May 2010
    View recommendations

    Sections for TA187

  8. Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

    Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

    Evidence summary
    Published
    26 March 2013

  9. Further research should focus on the extended use of telemetric adjustable pulmonary artery banding for ventricular retraining and for its use pending the resolution of ventricular septal defects. Data collection may provide useful information. NICE may review the procedure on publication of further evidence.

    adjustable reduction of pulmonary artery flow in infants with congenital heart defects, but there are uncertainties about which infants...

    Research recommendation
    Published
    9 June 2015

  10. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

    NICE guideline
    Last updated
    8 January 2026

    Sections for NG246

  11. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

    Interventional procedures guidance
    Published
    26 June 2015
    View recommendations

    Sections for IPG524

  12. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

    HealthTech guidance
    Published
    21 June 2017
    View recommendations

    Sections for HTG441

  13. Lumbar subcutaneous shunt (IPG68)

    Evidence-based recommendations on lumbar subcutaneous shunt. This involves using a shunt to drain excess cerebrospinal fluid away so that it doesn’t damage the brain or eyes.

    Interventional procedures guidance
    Published
    23 June 2004
    View recommendations

    Sections for IPG68

  14. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (TA242)

    Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    25 January 2012
    View recommendations

    Sections for TA242

  15. Molnupiravir for treating COVID-19 (TA1056)

    Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1056